Wistar study reveals innate tumor suppression mechanism

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

In a study published in Cancer Discovery, researchers from the Wistar Institute reported a key mechanism as to how p53 suppresses tumors. By comparing the mechanisms of wildtype and variant p53, the researchers discovered the mechanism by which p53 triggers immune function that, in turn, kills the tumor.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Nan ZhangNoam AuslanderNan Zhang and Noam Auslander, the Wistar Institute assistant professors, have both received independent funding totaling $1.2 million over the next three years for cancer research projects from the V Foundation for Cancer Research. The grants are awarded to cancer researchers deemed “V Scholars” and allow Zhang and Auslander to pursue separate projects aimed at new strategies to improve the effectiveness of certain cancer therapies.
The Wistar Institute’s president and CEO, Dario C. Altieri, and his team have demonstrated the role of Parkin—a protein implicated in Parkinson’s disease—in the body’s innate immune response to cancer. Parkin is not expressed in several cancers. Altieri and his team engineered cancer cells to re-express Parkin and found that Parkin contributes to the production of interferons, which activate and attract T cells to fight the tumor. The lab’s findings were published in The Journal of Clinical Investigation.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login